| Risk | Impact on Prophylaxis | Impact on Laboratory Monitoring | |
|---|---|---|---|
| Bacterial Infections | No increased risk (69) | None | None |
| BK Virus | No increased risk (69) | N/A | Standard monitoring (if indicated) |
| CMV | No increased risk compared to other regimens (69, 46) | Standard prophylaxis or preemptive therapy is required | None |
| EBV / PTLD | No increased risk, potentially protective (70) | None | None |
| Fungal Infections | Traditionally, no increased risk (69) though recent data somewhat conflicts (39) | None | None |
| HCV/HBV | Increased risk for HBV reactivation (68), lack of data regarding HCV | Consider HBV prophylaxis if evidence of chronic HBV infection (including core antibody positive) | Monitor for HBV reactivation if not taking prophylaxis and evidence of chronic HBV |
| HSV/HZV | No increased risk | None | None |
| Miscellaneous Infections | Increased risk for JC virus infection (cause of PML); No association with TB (53) | N/A | N/A |
| Pneumocystis | No increased risk (No impact on T cells) | Prophylaxis only if other high risk agents administered | None |
When rituximab is combined with ATG there appears to be an increased risk for infection related mortality.